Table 3.
Patients' characteristics for those in the primary analysis compared to those not in the primary analysis.
| Patients not in primary analysis n = 207 |
Patients in primary analysis n = 169 |
p value | |
|---|---|---|---|
| Trials | |||
| Ludman [27] | 12 (30%) | 28 (70%) | < 0.001 |
| Crimi [28] | 39 (51%) | 37 (49%) | |
| Garcia-Dorado [30] | 131 (74%) | 46 (26%) | |
| White [29] | 25 (30%) | 58 (70%) | |
| Randomization | |||
| Intervention | 107 (56%) | 84 (44%) | 0.39 |
| Placebo | 100 (54%) | 85 (46%) | |
| Age | 58 ± 12 | 59 ± 11 | 0.16 |
| Sex — male | 80 (42%) | 113 (58%) | < 0.001 |
| Risk factors | |||
| Smoking | 134 (61%) | 87 (39%) | 0.006 |
| Hypertension | 91 (55%) | 75 (45%) | 0.51 |
| Dyslipidemia | 62 (53%) | 55 (47%) | 0.33 |
| Diabetes mellitus | 30 (55%) | 25 (45%) | 0.52 |
| Family history of CAD | 41 (57%) | 31 (43%) | 0.41 |
| Onset to balloon time/min | 235 ± 118 | 192 ± 64 | < 0.001 |
| Artery involved | |||
| LAD | 114 (54%) | 97 (46%) | 0.36 |
| RCA | 31 (44%) | 40 (56%) | 0.02 |
| Cx | 62 (66%) | 32 (34%) | 0.009 |
| CMR details | |||
| LVEDV | 155 ± 39 | 153 ± 33 | 0.51 |
| LVESV | 81 ± 34 | 75 ± 25 | 0.56 |
| LVEF | 49 ± 11 | 52 ± 11 | 0.054 |
| MI size/%LV | 22 ± 12 | 22 ± 10 | 0.95 |
| AAR/%LV | 34 ± 13 | 32 ± 11 | 0.25 |
| MI size/%AAR | 63 ± 20 | 66 ± 21 | 0.08 |
| MVO/% | 111 (53%) | 98 (47%) | 0.23 |
CAD: coronary artery disease; LAD: left anterior descending artery; RCA: right coronary artery; Cx: circumflex artery; TIMI: Thrombolysis In Myocardial Infarction; PPCI: primary percutaneous coronary intervention; LVEDV: left ventricular end diastolic volume; LVESV: left ventricular end systolic volume; LVEF: left ventricular ejection fraction; AAR: area at risk; LV: left ventricle; MVO: microvascular obstruction.